Diarrhea prevention and prophylaxis with crofelemer in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and docetaxel or paclitaxel with or without carboplatin.

Authors

Jennifer Gao

National Cancer Institute at the National Institutes of Health, Washington, DC

Jennifer Gao , Ming Tony Tan , Sandra M. Swain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.

First Author: Nicholas Patrick McAndrew

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.

First Author: Sayeh Moazami Lavasani

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).

First Author: Laura Spring

insert_chart_outlined

Poster

2012 Breast Cancer Symposium

bookmark_border

Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).

First Author: Farrah Datko